Symbols
Symbols
Aime
Products
News
Market
Watchlist
Brokers
News
/
Stock
/
OTLK
OTLK
Content Types
Newswire
Articles
Latest News Updates
08:41
OTLK
--%
Outlook Therapeutics Resubmits BLA for ONS-5010 Wet AMD Treatment
08:37
OTLK
--%
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 Ophthalmic Bevacizumab Formulation.
Tuesday Sep 30, 2025
19:49
OTLK
--%
HC Wainwright & Co. Reaffirms Neutral Rating for Outlook Therapeutics with $1.00 Price Target
08:47
OTLK
--%
Outlook Therapeutics: HC Wainwright Raises PT to $1, Reiterates Neutral Rating
Monday Sep 29, 2025
18:05
OTLK
--%
Outlook Therapeutics Expects BLA Resubmission Before End of 2025
10:51
OTLK
--%
Outlook Therapeutics Updates on FDA Meeting for ONS-5010/LYTENAVA
09:48
OTLK
--%
Outlook Therapeutics Completes Type A Meeting with FDA on ONS-5010 BLA Resubmission.
Friday Sep 26, 2025
07:22
OTLK
--%
Outlook Therapeutics, Inc. shares fall 1.95% premarket as Wall Street futures mixed ahead of inflation data.
Monday Sep 22, 2025
07:01
OTLK
--%
Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.
Thursday Sep 04, 2025
11:08
BCTX
--%
+1
BriaCell's 15-min chart indicates a bearish KDJ Death Cross and Marubozu.
Wednesday Sep 03, 2025
12:59
OTLK
--%
Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA.
09:38
OTLK
--%
Outlook Therapeutics presents at EURETINA Congress on bevacizumab treatment.
09:36
OTLK
--%
Outlook Therapeutics to Present at EURETINA Innovation Spotlight
Tuesday Sep 02, 2025
13:50
OTLK
--%
Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010.
09:41
OTLK
--%
Outlook Therapeutics Submits Type A Meeting Request to FDA.
09:38
OTLK
--%
Outlook Therapeutics Seeks FDA Clarification on Confirmatory Evidence for ONS-5010 Approval
Friday Aug 29, 2025
19:05
OTLK
--%
Guggenheim Downgrades Outlook Therapeutics to Neutral, Maintains No Price Target
19:05
OTLK
--%
Outlook Therapeutics Receives CRL for Lytenava, Chardan Calls it a "Significant Setback"
19:05
OTLK
--%
Chardan Capital Maintains Neutral Rating for Outlook Therapeutics with $3.00 Price Target.
19:05
OTLK
--%
Outlook Therapeutics Downgraded to Hold by H.C. Wainwright Analyst